11 Dec 2013 Posted in News Release By Press Office
“The ABPI applauds the progress that has been made on the life sciences strategy in the two years since its launch. We also welcome the Government’s investment in life sciences and commitment to support more research and collaboration into dementia. The announcements made in today’s speech about investment from pharmaceutical companies and the research/trial funding boost show that the UK is attracting investment and being seen as a place to locate and work in life sciences.
“There is a strong and long-standing commitment from the pharmaceutical industry to invest in the UK. Whilst we can look back positively at what has been achieved, there are growing challenges that will have to be faced in 2014 and beyond to ensure that the UK remains an attractive place to invest. The pharmaceutical industry, the Government and the NHS need to work hand-in-hand, alongside global stakeholders, to ensure patients in the UK can access the innovative, life-changing medicines they need.”
Notes to Editor
You may also be interested in a blog we have posted today from our Medical, Innovation & Research Director, Dr Bina Rawal, titled: The G8 Dementia Summit: How the Industry can help to meet the dementia challenge:
About the ABPI
The ABPI represents innovative research-based biopharmaceutical companies, large, medium and small, leading an exciting new era of biosciences in the UK.
Our industry, a major contributor to the economy of the UK, brings life-saving and life-enhancing medicines to patients. Our members supply 90 per cent of all medicines used by the NHS, and are researching and developing over two-thirds of the current medicines pipeline, ensuring that the UK remains at the forefront of helping patients prevent and overcome diseases.
The ABPI is recognised by government as the industry body negotiating on behalf of the branded pharmaceutical industry, for statutory consultation requirements including the pricing scheme for medicines in the UK.
ABPI Press Office
Tel: +44 (0) 20 7747 1441 or +44 20 7747 1410
Mobile: +44 (0) 7808 641811 or +44 7850 312064